188 related articles for article (PubMed ID: 33757667)
1. Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China.
Chen D; Ye Z; Pi Z; Mizukami S; Aoyagi K; Jiang Y
Vaccine; 2021 Apr; 39(16):2237-2245. PubMed ID: 33757667
[TBL] [Abstract][Full Text] [Related]
2. [Based on a Markov model, cost-effectiveness analysis of influenza vaccination among people aged 60 years and older in Shenzhen].
Wu XL; Ye ZJ; Xie F; Huang DF; Kong TJ; Feng SX; Zhang YW; Jiang Y
Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Jul; 43(7):1140-1146. PubMed ID: 35856212
[No Abstract] [Full Text] [Related]
3. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
You JH; Wong WC; Ip M; Lee NL; Ho SC
J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study.
Ding H; Huang J; Ngai CH; Sun Q; Kwok KO; Wang HH; Chong M; Wong MC
Vaccine; 2022 Feb; 40(9):1282-1288. PubMed ID: 35094867
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y
Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414
[TBL] [Abstract][Full Text] [Related]
7. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
Brydak L; Roiz J; Faivre P; Reygrobellet C
Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
[TBL] [Abstract][Full Text] [Related]
8. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
Meier G; Gregg M; Poulsen Nautrup B
J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.
Lin CJ; Zimmerman RK; Smith KJ
Am J Manag Care; 2013 Jan; 19(1):e30-7. PubMed ID: 23379777
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F
Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.
Smith KJ; Lee BY; Nowalk MP; Raymund M; Zimmerman RK
Vaccine; 2010 Nov; 28(48):7620-5. PubMed ID: 20887828
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
[TBL] [Abstract][Full Text] [Related]
16. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
Kuhlmann A; von der Schulenburg JG
Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ
Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135
[No Abstract] [Full Text] [Related]
18. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China.
Sun X; Tang Y; Ma X; Guo X; Huang Z; Ren J; Qiu J; Jiang H; Lu Y
Front Public Health; 2021; 9():647725. PubMed ID: 34109145
[No Abstract] [Full Text] [Related]
19. Standing orders program of pneumococcal vaccination for hospitalized elderly patients in Hong Kong: A cost-effectiveness analysis.
Xing N; Cheung WY; Jiang M; You JHS
Am J Infect Control; 2019 Nov; 47(11):1302-1308. PubMed ID: 31266663
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
Mo X; Gai Tobe R; Liu X; Mori R
Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
